Certara (NASDAQ:CERT) Updates FY 2024 Earnings Guidance

Certara (NASDAQ:CERT) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 0.410-0.460 for the period, compared to the consensus earnings per share estimate of 0.430. The company issued revenue guidance of $385.0 million-$400.0 million, compared to the consensus revenue estimate of $388.5 million.

Certara Price Performance

Shares of Certara stock opened at $17.66 on Wednesday. The business’s fifty day moving average price is $17.71 and its 200 day moving average price is $16.42. The stock has a market capitalization of $2.83 billion, a P/E ratio of -50.46, a PEG ratio of 1.81 and a beta of 1.61. Certara has a twelve month low of $11.81 and a twelve month high of $23.54. The company has a current ratio of 2.62, a quick ratio of 2.62 and a debt-to-equity ratio of 0.28.

Certara (NASDAQ:CERT) last issued its quarterly earnings data on Thursday, February 29th. The company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.04). The company had revenue of $88.01 million for the quarter, compared to analyst estimates of $86.80 million. Certara had a positive return on equity of 4.33% and a negative net margin of 15.62%. As a group, research analysts anticipate that Certara will post 0.29 earnings per share for the current year.

Wall Street Analyst Weigh In

CERT has been the subject of several research analyst reports. JMP Securities initiated coverage on Certara in a report on Thursday, April 4th. They issued a market perform rating for the company. Jefferies Financial Group boosted their price objective on Certara from $14.00 to $15.50 and gave the company a hold rating in a report on Friday, March 1st. KeyCorp raised Certara from a sector weight rating to an overweight rating and set a $23.00 price objective for the company in a report on Wednesday, April 10th. Leerink Partnrs reissued a market perform rating on shares of Certara in a report on Monday, February 26th. Finally, SVB Leerink assumed coverage on Certara in a report on Monday, February 26th. They set a market perform rating and a $19.00 target price for the company. Seven research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, Certara presently has a consensus rating of Hold and an average price target of $20.06.

Insider Buying and Selling at Certara

In related news, SVP Richard M. Traynor sold 3,000 shares of the stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $18.00, for a total value of $54,000.00. Following the completion of the sale, the senior vice president now owns 173,524 shares in the company, valued at $3,123,432. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In related news, SVP Richard M. Traynor sold 3,000 shares of the stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $18.00, for a total value of $54,000.00. Following the completion of the sale, the senior vice president now owns 173,524 shares in the company, valued at $3,123,432. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Patrick F. Smith sold 14,427 shares of the stock in a transaction dated Tuesday, April 2nd. The shares were sold at an average price of $16.85, for a total transaction of $243,094.95. Following the completion of the sale, the insider now owns 50,091 shares of the company’s stock, valued at approximately $844,033.35. The disclosure for this sale can be found here. Insiders sold 23,427 shares of company stock worth $405,095 over the last ninety days. Company insiders own 2.39% of the company’s stock.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.